EMCDDA technical report on the new psychoactive substance N,Ndiethyl- 2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene)

Table of contents

• 1. Summary
• 2. Chemical and physical properties, methods and the precursors used for manufacture or extraction
  • 2.1 Background
  • 2.2 Names and chemical structur
  • 2.3 Physical properties
  • 2.4 Methods and chemical precursors used for the manufacture or extraction
  • 2.5 Methods for identification and analysis
  • 2.6 Dosage regimens
• 3. Legitimate use
  • 3.1 Summary
  • 3.2 Medical use
  • 3.3 Industrial, commercial, and scientific use
• 4. Pharmacological and toxicological properties
  • 4.1 Summary
  • 4.1 Pharmacodynamics
  • 4.2 Psychological and behavioural effects
  • 4.3 Safety pharmacolog
  • 4.4 Pharmacokinetics
  • 4.5 Toxicology
  • 4.6 Abuse liability and dependence producing potential
• 5. Extent and patterns of use, availability, and potential for diffusion
  • 5.1 Summary
  • 5.2 Information from seizures
  • 5.3 Information from collected samples
  • 5.4 Information from biological samples
• 6. Health risks
  • 6.1 Summary
  • 6.2 Acute health effects
  • 6.3 Chronic health effects
• 7. Social risks
  • 7.1 Individual social risks
  • 7.2 Possible effects on direct social environment
  • 7.3 Possible effects on society as a whole
  • 7.4 Economic costs
  • 7.5 Possible effects related to the cultural context, for example marginalisation.
  • 7.6 Possible appeal to specific population groups within the general population
  • 7.7 Involvement of criminal groups in the manufacture, distribution and distribution methods, and trafficking
• 8. Other relevant information
  • 8.1 Information on restrictive measures
• 9. References